The integral dose and the dose to the organ at risk were calculated using the following angiographic techniques: 1. Intravenous DSA in the neck, 2. Intravenous DSA in the skull, 3. Intra-arterial DSA in the skull in searching for an aneurysm. This was compared with 4. 105 mm. camera technique and 5. An imaging plate technique. These methods have been compared with reference to dose and diagnostic value. Desirable developments for angiography in the future are discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-2008-1048723 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Combination of Intravenous Immunoglobulin, Dexamethasone, and a High Dose of Mononuclear Cells Transfusion: An Effective Strategy for Decreasing Donor-Specific Antibodies During Haploidentical Hematopoietic Stem Cell Transplantation.
Cell Transplant
January 2025
Department of Hematology, 920th Hospital of Joint Logistics Support Force, Kunming, China.
Donor-specific antibodies (DSAs) are essential causes of graft rejection in haploidentical hematopoietic stem cell transplantation (haplo-HSCT). DSAs are unavoidable for some patients who have no alternative donor. Effective interventions to reduce DSAs are still needed, and the cost of the current therapies is relatively high.
View Article and Find Full Text PDFSuccessful desensitization of donor-specific antibodies in a single cord blood transplant recipient.
Hematology
December 2025
Cellular Therapy & Transplantation Program, Hopital Maisonneuve-Rosemont, Universite de Montreal, Montreal, Quebec, Canada.
Umbilical cord blood (UCB) represents a valuable graft source in the absence of a human leukocyte antigen (HLA)-matched donor for hematopoietic cell transplantation (HCT). Donor-specific anti-HLA antibodies (DSAs), targeting grafts with mismatched HLA antigens, pose a significant obstacle by increasing the risk of primary graft failure, delayed engraftment, and decreased survival. Existing literature on HLA desensitization has primarily focused on haploidentical transplants, and there is a lack of experience regarding the optimal strategy in UCB transplantation.
View Article and Find Full Text PDFEvaluation of the Effect of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease.
Clin Pharmacokinet
January 2025
Clinical Pharmacology, AbbVie Inc., Dept R4PK, Bldg AP31-3, 1 North Waukegan Road, North Chicago, IL, 60064-1802, USA.
Background And Objective: The objective of this study was to characterize the effects of risankizumab on the pharmacokinetics of cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A substrates in patients with moderately to severely active Crohn's disease (CD) or ulcerative colitis (UC) using a cocktail approach.
Methods: Patients with CD or UC (n = 20) received single doses of probe substrates for CYP1A2 (caffeine 100 mg), CYP2C9 (warfarin 10 mg), CYP2C19 (omeprazole 20 mg), CYP2D6 (metoprolol 50 mg), and CYP3A (midazolam 2 mg) before and after intravenous infusions of risankizumab 1800 mg once every 4 weeks for four doses. Serial blood samples were collected for determination of concentrations of the CYP probe drugs and metabolites with and without risankizumab.
The cortical vein opacification score (COVES) is independently associated with DSA ASITN collateral score.
AJNR Am J Neuroradiol
November 2024
From the Department of Radiology and Radiological Sciences (D.A.L., A.B.B., H.S., R.W., J.M., V.Y.), and Department of Neurology (A.E.H.), Johns Hopkins University, Baltimore, MD, USA; Department of Neuroradiology (D.A.L., S.A., M.K., A.T.R.), and Department of Biostatistics (S.W.), West Virginia University, Morgantown, WV, USA; Cooper Medical School of Rowan University (M.K.), Camden, NJ, USA; Department of Neurology (J.J.H., G.W.A.), Stanford University, Stanford, CA, USA; Department of Radiology (A.A.D.), Harvard Medical School, Boston, MA, USA; Department of Radiology, Neuroendovascular Division (T.D.F.), University Medical Center Münster, Germany; Department of Neuroradiology (M.W.), MD Anderson Medical Center, Houston, TX, USA; Department of Radiology (K.N.), University of California San Francisco, CA, USA.
: Pretreatment CTA-based Cortical Vein Opacification Score (COVES) has been shown to predict good functional outcomes at 90 days in patients with acute ischemic stroke secondary to large vessel occlusion (AIS-LVO). This is thought to be related to its ability to measure collateral status (CS). However, its association with the reference standard test, the DSA-based American Society of Interventional and Therapeutic Neuroradiology (ASITN) collateral score, has yet to be established.
View Article and Find Full Text PDFEfficacy of a Standardized Regimen of Therapeutic Plasma Exchange and IVIG for Treatment of Antibody-Mediated Rejection in Lung Transplant Recipients.
J Clin Apher
December 2024
Department of Pathology, UT Southwestern Medical Center, Dallas, Texas, USA.
Antibody-mediated rejection (AMR) in lung transplantation has been associated with poor long-term clinical course and is a risk factor for chronic lung allograft dysfunction and graft loss. Appropriate management of AMR is necessary to improve graft survival in lung transplant recipients. There is currently no standardized approach to the treatment of lung AMR, and practices vary by institution.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!